Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Phase 3 Terminated 169 enrolled Navidea Biopharmaceuticals

NaSingle-groupOpen-labelDiagnostic

Summary

This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.

Timeline

Start: 2022-03-02
Primary completion: 2024-07-09
Completion: 2024-07-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tilmanocept	Diagnostic / imaging agent	—	—

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Summary

Timeline

Drugs

Indications